Abstract
Introduction and objectivesMacitentan, a novel dual endothelin receptor antagonist (ERA), significantly reduced morbidity and mortality in pulmonary arterial hypertension (PAH) patients in the SERAPHIN trial (NCT00660179), the first event-driven outcomes...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have